East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails

Cystic fibrosis patients were hopeful that the drug could reduce their pill burden; instead a late-stage clinical trial failure caused Anthera Pharmaceutical's stock to dip as low as 40 cents per share.